(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 November 2013 (21.11.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/171712 A1

(51) International Patent Classification:
C07D 471/04 (2006.01) *A61P 25/28* (2006.01)
A61K 31/5513 (2006.01)

(21) International Application Number:
PCT/IB2013/054014

(22) International Filing Date:
16 May 2013 (16.05.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

12168186.0	16 May 2012 (16.05.2012)	EP
12195875.5	6 December 2012 (06.12.2012)	EP
12197010.7	13 December 2012 (13.12.2012)	EP
13159178.6	14 March 2013 (14.03.2013)	EP

(71) Applicant: **JANSSEN PHARMACEUTICALS, INC.** [US/US]; 1125 Trenton-Harbourton Road, Titusville, New Jersey 08560 (US).

(72) Inventors: **ROMBOUTS, Frederik, Jan, Rita**; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE). **TRABANCO-SUÁREZ, Andrés, Avelino**; c/o Janssen-Cilag S.A., Calle Jarama, 75, Poligono Industrial, E-45007 Toledo (ES). **GIJSEN, Henricus, Jacobus, Maria**; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE). **MACDONALD, Gregor, James**; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE). **BISCHOFF, François Paul**; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE). **ALONSO-de DIEGO, Sergio-Alvar**; c/o Janssen-Cilag S.A., Calle Jarama, 75, Poligono Industrial, E-45007 Toledo (ES). **VELTER, Adriana, Ingrid**; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE). **VAN ROOSBROECK, Yves, Emiel, Maria**; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

(54) Title: SUBSTITUTED 3, 4 - DIHYDRO - 2H - PYRIDO [1, 2 -A] PYRAZINE - 1, 6 - DIONE DERIVATIVES USEFUL FOR THE TREATMENT OF (INTER ALIA) ALZHEIMER'S DISEASE



(I)

(57) Abstract: The present invention is concerned with novel substituted 3,4-dihydro-2H-pyrido[1,2- a]pyrazine-1,6-dione derivatives of Formula (I) wherein R^1, R^2, R^3, R^4, R^5, Z and X have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

WO 2013/171712 A1